Cryo Cell International (CCEL) Equity Average (2011 - 2026)

Cryo Cell International has disclosed Equity Average across 16 years of filings, most recently posting -$18.5 million for Q1 2026.

• In Q1 2026, Equity Average fell 32.77% year-over-year to -$18.5 million; the TTM figure through Feb 2026 stood at -$18.5 million (down 32.77% YoY), while the FY2025 annual figure was -$15.9 million, down 31.24% from the prior year.
• Equity Average fell to -$18.5 million in Q1 2026, from -$16.7 million in the prior quarter.
• Over the last five years, Equity Average for CCEL reached as high as $4.3 million in Q2 2022 and fell as low as -$18.5 million in Q1 2026.
• The 5-year median for Equity Average is -$10.2 million (2024), against an average of -$7.2 million.
• Annual changes were most pronounced in 2022 — Equity Average surged 293.47% — and 2024, when it slumped 2221.24%.
• A 5-year view of Equity Average shows it stood at -$2.0 million in 2022, then tumbled by 182.55% to -$5.5 million in 2023, then plunged by 106.16% to -$11.4 million in 2024, then sank by 46.82% to -$16.7 million in 2025, then dropped by 10.67% to -$18.5 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered -$18.5 million, -$16.7 million, and -$15.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.